Oral Contraceptives May Protect Against Rheumatoid Arthritis
By Lori Solomon HealthDay Reporter
WEDNESDAY, Nov. 8, 2023 -- Oral contraceptive use appears to protect against rheumatoid arthritis (RA), while menopausal hormone therapy (MHT) use may increase the risk for late-onset RA, according to a study published online Sept. 29 in Rheumatology.
Fatemeh Hadizadeh, M.D., Ph.D., from Uppsala University in Sweden, and colleagues estimated the effects of exogenous hormones on the development of RA, both during the reproductive lifespan and later in life. The analysis included 236,602 oral contraceptive users and 102,466 MHT users participating in the U.K. Biobank.
The researchers found that oral contraceptive use was associated with a decreased risk for RA in ever-users (hazard ratio [HR], 0.89; 95 percent confidence interval [CI], 0.82 to 0.96). The association was seen in both current (HR, 0.81; 95 percent CI, 0.73 to 0.91) and former users (HR, 0.92; 95 percent CI, 0.84 to 1.00) versus never-users. MHT use was associated with an increased risk for late-onset RA in ever-users (HR, 1.16; 95 percent CI, 1.06 to 1.26), as well as in former users (HR, 1.13; 95 percent CI, 1.03 to 1.24) versus never-users.
"The observed presence of two distinct effects of exposure to exogenous hormones on risk of RA could be related to differences in the hormones' functions in the body, variations in the response to hormones in different reproductive statuses, or heterogeneity between early-onset RA and late-onset RA," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Risk for Most Cardiovascular Diseases No Higher With Inflammatory Bowel Disease
FRIDAY, May 3, 2024 -- Among postmenopausal women with inflammatory bowel disease (IBD), there is no higher risk for cardiovascular disease (CVD) compared with women without IBD...
Long-Term Study of Postmenopausal Women Does Not Support Many Preventive Therapies
THURSDAY, May 2, 2024 -- The longitudinal Women's Health Initiative trials do not support hormone therapy for cardiovascular disease prevention, calcium and vitamin D...
Menopausal Hormone Therapy Use Beyond 65 Years Beneficial
TUESDAY, April 16, 2024 -- Use of menopausal hormone therapy beyond age 65 years is associated with risk reductions in mortality as well as specific cancers and cardiovascular...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.